CS Medica A/S announced the results of a single-arm clinical trial evaluating the efficacy of Nasal Protect Gel in treating hay fever/allergic rhinitis. The study enrolled 60 subjects with a history of hay fever/allergic rhinitis during the high season of pollen for a period of two weeks. The results were overwhelmingly positive, with none of the subjects reporting any allergy reaction during the study.

The trial's primary objective was to evaluate the efficacy of Nasal Protect Gel in reducing hay fever/allergic rhinitis symptoms. The results demonstrated that 100% of the subjects reported no pollen allergy, 90% reported reduced nasal obstruction and 92% reported reduced sneezing episodes and 75% of the subjects reported a decrease in their TNSS score (Total nasal symptoms score), a widely used questionnaire that evaluates the severity of main symptoms of allergic rhinitis in different countries. Importantly, none of the subjects reported any adverse events or side effects during the study, and CS MEDICA has not received any adverse events from the market. This suggests that Nasal Protect Gel is safe for use and could provide a much-needed solution for individuals suffering from hay fever/allergic rhinitis.

Nasal Protect Gel is already available on the market and has been well-received by consumers. Nasal Protect Gel is currently launched in the following countries Denmark, Sweden, Germany, United Kingdom, Spain, Serbia, Croatia, and The Netherlands, with orders pending in Romania, Israel, Palestine, and Kuwait. With the positive results from this study, CS MEDICA is optimistic about the future of Nasal Protect Gel as a safe and effective treatment option for hay fever/allergic rhinitis.